BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp cut its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 14.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 23,215 shares of the specialty pharmaceutical company’s stock after selling 4,021 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Jazz Pharmaceuticals PLC were worth $3,610,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. DekaBank Deutsche Girozentrale increased its position in shares of Jazz Pharmaceuticals PLC by 8.2% in the first quarter. DekaBank Deutsche Girozentrale now owns 59,683 shares of the specialty pharmaceutical company’s stock valued at $8,725,000 after buying an additional 4,527 shares during the last quarter. American Century Companies Inc. increased its position in shares of Jazz Pharmaceuticals PLC by 1,453.2% in the first quarter. American Century Companies Inc. now owns 235,806 shares of the specialty pharmaceutical company’s stock valued at $34,223,000 after buying an additional 220,624 shares during the last quarter. Eqis Capital Management Inc. increased its position in shares of Jazz Pharmaceuticals PLC by 1.3% in the first quarter. Eqis Capital Management Inc. now owns 11,200 shares of the specialty pharmaceutical company’s stock valued at $1,625,000 after buying an additional 140 shares during the last quarter. Adell Harriman & Carpenter Inc. purchased a new position in shares of Jazz Pharmaceuticals PLC during the first quarter valued at approximately $1,559,000. Finally, C WorldWide Group Holding A S increased its position in shares of Jazz Pharmaceuticals PLC by 3.7% in the first quarter. C WorldWide Group Holding A S now owns 98,465 shares of the specialty pharmaceutical company’s stock valued at $14,290,000 after buying an additional 3,493 shares during the last quarter. 87.22% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals PLC (NASDAQ JAZZ) opened at 146.50 on Thursday. Jazz Pharmaceuticals PLC has a 52 week low of $95.80 and a 52 week high of $163.75. The company has a market cap of $8.80 billion, a PE ratio of 22.57 and a beta of 1.10. The company has a 50-day moving average of $152.50 and a 200-day moving average of $148.27.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.85 by $0.13. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The company had revenue of $394.39 million for the quarter, compared to analysts’ expectations of $410.83 million. During the same quarter last year, the company earned $2.67 EPS. Jazz Pharmaceuticals PLC’s revenue for the quarter was up 3.5% compared to the same quarter last year. On average, equities analysts expect that Jazz Pharmaceuticals PLC will post $10.87 EPS for the current year.

WARNING: “BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Has $3.61 Million Stake in Jazz Pharmaceuticals PLC (JAZZ)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/24/british-columbia-investment-management-corp-has-3-61-million-stake-in-jazz-pharmaceuticals-plc-jazz.html.

Several analysts recently weighed in on the stock. Zacks Investment Research cut shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a report on Tuesday, May 2nd. Cantor Fitzgerald reiterated a “buy” rating and issued a $197.00 price target on shares of Jazz Pharmaceuticals PLC in a report on Tuesday, June 27th. Royal Bank Of Canada set a $210.00 price target on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a report on Tuesday, June 27th. Cowen and Company reiterated an “outperform” rating and issued a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, May 10th. Finally, Leerink Swann set a $179.00 price target on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a report on Thursday, April 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nineteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $182.72.

In other news, Director Rick E. Winningham sold 5,000 shares of the stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $150.00, for a total value of $750,000.00. Following the transaction, the director now owns 10,391 shares in the company, valued at approximately $1,558,650. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Michael Patrick Miller sold 200 shares of the stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $150.65, for a total value of $30,130.00. Following the completion of the transaction, the executive vice president now owns 22,223 shares in the company, valued at approximately $3,347,894.95. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,566 shares of company stock worth $1,921,138. 4.30% of the stock is owned by company insiders.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.